6-Feruloylnodakenin

CAS No. 131623-14-8

6-Feruloylnodakenin( —— )

Catalog No. M31969 CAS No. 131623-14-8

6'-Feruloylnodakenin is a natural product for research related to life sciences.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1017 In Stock
10MG 1378 In Stock
25MG 2043 In Stock
50MG 2678 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    6-Feruloylnodakenin
  • Note
    Research use only, not for human use.
  • Brief Description
    6'-Feruloylnodakenin is a natural product for research related to life sciences.
  • Description
    6'-Feruloylnodakenin is a natural product for research related to life sciences.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    131623-14-8
  • Formula Weight
    584.6
  • Molecular Formula
    C30H32O12
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Pinocembrin 7-O-beta...

    Pinocembrin 7-O-beta-D-glucoside is a natual product isolated from?Penthorum chinense Pursh.

  • L-allo-Isoleucine

    L-alloisoleucine is a branched chain amino acid and is a stereoisomer of L-isoleucine. It is a common constituent of human plasma (albeit at low levels). L-alloisoleucine is produced as a byproduct of isoleucine transamination. Plasma L-alloisoleucine which is derived from L-isoleucine in vivo can be used for the diagnosis of maple syrup urine disease (MSUD) a genetic disorder.

  • 5-HT2B antagonist-1

    5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 of 33.4 nM, suitable for studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease, or gastrointestinal disease .